SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection

The goal of this clinical trial is to evaluate the safety profile and tolerability of SDT-M001 injection in NSCLC patients with driver-gene-negative and negative PD-L1 expression after radical surgical resection; to determine the recommended Phase II dose (RP2D).

Trial Details

NCT ID

NCT07096882

Phase

PHASE1

Sponsor

Cytocraft Biopharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

SDT-M001 injection

Locations (sample)

Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

All participants must be informed of the trial before any examinations stipulated in this trial are initiated, voluntarily sign the written informe…
Age ranges from 18 to 70 years old (including threshold), regardless of gender.
For participants diagnosed with primary NSCLC according to the standards of the "Chinese Medical Association guideline for clinical diagnosis and t…
There is no disease recurrence (including local recurrence) after radical surgical resection (R0) treatment, and the estimated time of apheresis is…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →